Lando, Howard M <br/><br/>
Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.  [electronic resource] 

 -  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists   
 - 472-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1934-2403 
<br/><br/><label>Standard No.: </label>10.4158/EP11290.OR  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--adverse effects<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptides--adverse effects<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Drug Monitoring<br/>Exenatide<br/>Female<br/>Glucagon-Like Peptide 1--agonists<br/>Glucagon-Like Peptide-1 Receptor<br/>Humans<br/>Hypoglycemic Agents--adverse effects<br/>Lipase--blood<br/>Male<br/>Middle Aged<br/>Pancreas--drug effects<br/>Pancreatic alpha-Amylases--blood<br/>Pancreatitis--chemically induced<br/>Peptides--adverse effects<br/>Pyrazines--adverse effects<br/>Receptors, Glucagon--agonists<br/>Reproducibility of Results<br/>Severity of Illness Index<br/>Sitagliptin Phosphate<br/>Triazoles--adverse effects<br/>Venoms--adverse effects